Saturday, July 11, 2026

Drug profile · INN

sipavibart

sipavibart (KAVIGALE) is an FDA-listed pharmaceutical active ingredient.

EMA: approved PMDA: approved Antiinfectives for systemic use (J06) J06BD09
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — sipavibart
Class
Antiinfectives for systemic use (J06)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

sipavibart (KAVIGALE) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN sipavibart
Brand KAVIGALE
Therapeutic class Antiinfectives for systemic use (J06)
ATC code J06BD09

Approval history

Authority Status Date
EMA approved
PMDA approved

Pipeline programs

  1. D7000C00001 Phase 3 · AstraZeneca · COVID-19

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is sipavibart?

sipavibart (KAVIGALE) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for sipavibart?

KAVIGALE is a marketed brand name for sipavibart. Check FDA Drugs@FDA for the current US label holder and prescribing information.